季節性インフルエンザワクチン市場：タイプ別、ワクチンタイプ別、価数別、年齢層別、流通チャネル別、地域別、2026～2032年

季節性インフルエンザワクチン市場の評価、2026～2032年

世界的に報告されるインフルエンザ患者数の増加に伴い、インフルエンザワクチンの需要が増加し、市場の拡大に拍車がかかると予想されます。インフルエンザワクチン市場は今後数年間、世界規模で急速に拡大すると予測されています。この背景には、高齢者人口の増加、認知度の向上、政府によるワクチン接種キャンペーン、インフルエンザの発生頻度の増加があります。季節性インフルエンザワクチン市場は、2024年には約79億7,000万米ドルと評価され、2032年には165億9,000万米ドルに達すると予測されています。

豚インフルエンザワクチンのようなインフルエンザ予防接種を隔離された地域でも受けられるようにするため、市場参入企業と各国政府との協力が増えれば、市場の成長が加速すると予想されます。これにより、市場は2026年から2032年にかけてCAGR 8.2%で成長します。

季節性インフルエンザワクチン市場定義/概要

インフルエンザワクチンは、インフルエンザ予防接種としても知られています。このワクチンは感染症を予防します。呼吸器系を侵し、頭痛、だるさ、鼻水、発熱、筋肉痛、鼻づまりなどの症状を引き起こします。感染者の咳やくしゃみによって急速に広がる感染症で、軽症から重症までを引き起こします。

季節性インフルエンザは、インフルエンザウイルスによって引き起こされる再発性の呼吸器疾患であり、その診断、治療、予防に関する経済活動を季節性インフルエンザ市場と呼ぶ。

現在の市場環境では、世界保健機関（WHO）、疾病対策予防センター（CDC）などの政府機関が、認可された多くの季節性インフルエンザワクチンを処方しています。さらに、WHOは世界インフルエンザ計画とGISRSを開始し、その他の活動とともに世界のインフルエンザの活動を監視しています。

さらに、インフルエンザワクチン市場の拡大は、先進国、新興国ともに、政府のイニシアティブによる定期的なワクチン接種プログラムの増加や、これらのプログラムにインフルエンザワクチン接種が含まれていることに起因しています。世界のインフルエンザワクチン市場に関する調査は、業界の包括的な分析を提供します。

季節性インフルエンザワクチン別感染予防の主要な変動要因とは？

WHOによると、世界の人口の増加、季節性インフルエンザワクチンは

妊娠中の女性、6～59ヶ月の子供、高齢者、ヘルスケアワーカーを含む利用可能なライセンスワクチンを取得しているグループへの合併症リスクの上昇。

インフルエンザを予防する最も効果的な方法は、60年以上使用されている信頼性の高い予防接種を使用することです。インフルエンザウイルスは常に進化し、変化しているため、インフルエンザから身を守るためには、毎年のワクチン接種が推奨されます。

インフルエンザに対する認識と予防接種プログラムの増加は、予防接種率の向上と市場の成長につながっています。インフルエンザに関連した疾病の負担の増大は、深刻なアウトブレイクやパンデミックの可能性と相まって、予防対策としての季節性インフルエンザワクチンの需要を煽っています。

細胞ベースや組み換え法などのワクチン技術の進歩により、これらのワクチンの効率性、安全性、有効性が向上しています。世界保健機関（WHO）や疾病対策予防センター（Centers for Disease Control and Prevention）などの国際機関は、病気の感染を減らし、脆弱な人々を守るための予防戦略として、季節性インフルエンザのワクチン接種を提唱しています。

中低所得国でのワクチン接種キャンペーンを含む世界の予防接種イニシアチブは、世界中でインフルエンザワクチンへのアクセスを拡大することにより、市場の成長に寄与しています。ヘルスケアプロバイダーや医療機関からの需要は、毎年のワクチン接種の推奨と相まって、インフルエンザシーズン中にワクチン接種サービスを求める個人の増加に伴い、市場成長の原動力となっています。COVID-19パンデミックは、インフルエンザのような呼吸器系ウイルスに対する効果的なワクチン接種戦略の重要性を浮き彫りにし、政府、ヘルスケア機関、製薬企業はインフルエンザワクチンの研究開発および流通を優先しています。

大手ヘルスケア企業は、最先端の治療法としてワクチン開発に多大な労力と資金を投じています。その一例として、2021年8月、Sequirus社は自己増幅型mRNAという将来のインフルエンザワクチン技術に投資しました。

季節性インフルエンザワクチンの副作用は？

インフルエンザワクチンの需要は、耐久性、有効性を高め、副作用の問題に対処するために研究開発が続けられています。さらに、各地域で入手しやすく手頃な価格で提供するためには、市場の可能性を実現することが不可欠です。

どのようなワクチンにも、発疹、発熱、疼痛、痛み、悪寒など、身体に様々な影響を与える副作用が含まれており、市場の成長能力を制限しています。地方では教育や経験が不足しています。そのため、子どもたちは予防接種を受けず、幼少期からウイルス性インフルエンザに感染するリスクが高まっています。ワクチン接種に対する国民の認識や信頼は、ネガティブな宣伝に取り囲まれているため、市場の成長を妨げる可能性があります。

季節性インフルエンザの予防接種を受けることの利点は、危険性を上回る。市場は、この制約を克服し、懸念事項を巧みに解決し、ワクチンの安全性を促進することにより、より広範なインフルエンザワクチンの使用を保証することができます。インフルエンザウイルスは、ワクチン効果をシーズンごとに決められた流行株まで低下させるため、ワクチンには限界があります。

米国国立医学図書館によると、COVID-19ワクチンと季節性インフルエンザワクチンを比較した場合、両ワクチンに含まれる重篤な症例の割合や死亡率は限定的であるといいます。季節性インフルエンザワクチンはCOVID-19よりも早く移行します。

目次

第1章 季節性インフルエンザワクチンの世界市場導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 季節性インフルエンザワクチンの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 季節性インフルエンザワクチンの世界市場：タイプ別

• 概要
• 不活化ワクチン
• 生ワクチン

第6章 季節性インフルエンザワクチンの世界市場：ワクチンタイプ別

• 概要
• 4価ワクチン
• 3価ワクチン

第7章 季節性インフルエンザワクチンの世界市場：価数別

• 概要
• 4価
• 3価

第8章 季節性インフルエンザワクチンの世界市場：投与経路別

• 概要
• 注射剤
• 鼻腔スプレー

第9章 季節性インフルエンザワクチンの世界市場：年齢層別

• 概要
• 小児
• 成人

第10章 季節性インフルエンザワクチンの世界市場：流通チャネル別

• 概要
• 病院・小売薬局
• 政府・機関供給

第11章 季節性インフルエンザワクチンの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第12章 世界の季節性インフルエンザワクチン市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第13章 企業プロファイル

• Sanofi
• Merck & Co
• Novartis
• GlaxoSmithKline
• Changsheng Bio-Technology Co., Ltd.
• Abbott Laboratories
• Aleph Biomedical

第14章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第15章 付録

• 関連調査

Seasonal Influenza Vaccine Market Valuation-2026-2032

The demand for influenza vaccines is expected to increase in response to the rising number of influenza cases reported globally, fueling the market's expansion. The market for influenza vaccines is anticipated to expand quickly on a global scale over the next years. This can be attributed to the growth in elderly population, awareness, and government vaccination campaigns, as well as a rise in frequency of the flu. The seasonal influenza vaccine market was valued at around USD 7.97 Billion in 2024 and projected to reach USD 16.59 Billion valued in 2032.

It is anticipated that an increase in collaborations between industry participants and governments to guarantee the availability of flu shots, like the swine flu vaccine, in isolated regions will quicken market growth. It enables the market to grow at a CAGR of 8.2% from 2026-2032.

Seasonal Influenza Vaccine Market: Definition/ Overview

Influenza Vaccine is also known as flu shots. This vaccines protect against infection. It affects the respiratory system and causes symptoms such as headaches, lethargy, runny nose, fever, muscular aches, and congestion. Infection that spreads quickly through an infected person's cough and sneezes and can cause mild to severe illness.

The economic activity related to the diagnosis, treatment, and prevention of seasonal influenza, a recurrent respiratory ailment brought on by influenza viruses, is referred to as the seasonal influenza market.

The disease in the current market environment, the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and other governmental agencies prescribe a number of licensed seasonal influenza vaccines. Moreover, the WHO has started the Global Influenza Program and GISRS, which work along with other organizations to monitor influenza activity worldwide.

Furthermore, increase of the influenza vaccine market is attributed to the growth of routine vaccination programs with government initiatives and inclusion of influenza vaccinations in these programs in both developed and developing nations. The study on the global influenza vaccine market offers a comprehensive analysis of the industry.

What are the Key Variables Factors for Seasonal Influenza Vaccines to Protect Agent Influence Disease?

The increasing population globally according to WHO, sessional influenza vaccines are

elevated risk complications to the group of pregnant women, children at the age of 6-59 months, old peoples, are getting licensed vaccines available including healthcare workers.

Most effective way to protect agent influenza disease by using reliable immunizations that have been in use for more than 60 years. An annual vaccination is advised to guard against influenza as the virus is ever-evolving and changing to protect it eroding.

The increasing awareness and vaccination programs about influenza is leading to higher vaccination rates and market growth. The growing burden of influenza-related illness, coupled with the potential for severe outbreaks or pandemics, has fueled demand for seasonal influenza vaccines as a preventive measure.

Advancements in vaccine technology, such as cell-based and recombinant methods, have improved the efficiency, safety, and effectiveness of these vaccines. International organizations like the World Health Organization and Centers for Disease Control and Prevention advocate for seasonal influenza vaccination as a preventive strategy to reduce disease transmission and protect vulnerable populations.

Global immunization initiatives, including vaccination campaigns in low- and middle-income countries, contribute to market growth by expanding access to influenza vaccines worldwide. Demand from healthcare providers and institutions, coupled with recommendations for annual vaccination, drives market growth as more individuals seek vaccination services during the influenza season. The COVID-19 pandemic has highlighted the importance of effective vaccination strategies against respiratory viruses like influenza, with governments, healthcare agencies, and pharmaceutical companies prioritizing research, development, and distribution of influenza vaccines.

Major healthcare companies are investing a great deal of effort and money into developing vaccines as cutting-edge treatments. As an illustration, in August 2021, Seqirus invested in the future influenza vaccine technology of self-amplifying mRNA.

What are the Side Effects of the Seasonal Influenza Vaccines?

The demand for influenza vaccines ongoing in research and development to enhance durability, efficacy, and address adverse effect issues. In additionally realizing the market potential is essential to provide accessibility and affordability across every region.

Any vaccines contain a number of side effects that can affect the body in many ways, including rashes, fever, pain, soreness, chills, and many more that limit the market's ability to grow. In rural areas there is a shortage of education and experience. Due to that children's are not vaccinated increasing the risk of contracting the viral flu from an early age. Public awareness or the trust about the vaccination can hinder the market growth because of negative publicity surrounding.

The advantages of getting vaccinated against seasonal influenza outweigh the dangers. The market may overcome this constraint and guarantee broader influenza vaccine use by skillfully resolving concerns and promoting vaccine safety. The virus reduce the vaccine effectiveness to the prevalent strain predicated for every season, which makes limitation of vaccines.

According to the National Library of Medicine, comparing the COVID-19 vaccine and seasonal influenza vaccine they may contain limited fraction of critical cases or morality rate. The seasonal influenza vaccine can transfer faster than the COVID-19.

Category-Wise Acumens

What Kind of Effectiveness Offered by Inactive Product to Contribute to Leading Position in Seasonal Influenza Vaccines Market?

As industry estimates the inactivated category will control the majority of the market in 2023. Industrialists' increasing focus on vaccines is driving a demand for inactivated vaccines in both developed and developing nations, as they are standardized based on specific virus strains. The greatest CAGR of the category over the projection period is primarily owing to the rising demand and high influenza prevalence.

There are ample evidence of their efficacy. Inactive Influenza Vaccines (IIVs) have a lengthy history building market demand, developing confidence, and offering significant protection against seasonal influenza viruses. When the circulating strains of the virus match the vaccination, they induce developed protection by targeting specific influenza antigens.

The safety profile of IIVs is very good. They are suitable for a wide spectrum of people and have moderate, transient negative effects.

Live attenuated category is expected to expand more slowly because of the many obstacles that companies must overcome to develop and approve vaccines. Furthermore, certain patients such as those with weak immune systems, asthma, and pregnant women should not receive the live attenuated vaccination.

How the Adoption of Seasonal Influenza Vaccines is Increasing in the Adults?

The majority of the market for seasonal influenza vaccinations is occupied by adults. Individuals with pre-existing medical disorders are more susceptible to serious influenza-related consequences, such as hospitalization and maybe fatality. The need for adult vaccinations is fueled by the necessity of vaccination for their protection. This is further supported by public health recommendations, which strongly advise high-risk persons to have an annual influenza vaccination.

The adult age group held a major share of the worldwide influenza vaccine market in terms of market share in 2022. There are significantly more adults than children in the population. The World Population Review of 2020 estimates that there were around 46 Billion adults over the age of 18, and approximately 1.2 Billion children between the ages of 12 and 18.

Furthermore, fewer influenza vaccinations are available for children than for adults. For example, the first COVID-19 vaccine approved in the United States was the Pfizer-BioNTech vaccine, and it was only approved for use in adults 16 years of age and older. As a result, adults are more likely than younger people to receive vaccinations.

Country/Region-wise Acumens

Does North America Hold Highest Market Share in the Seasonal Influenza Vaccines Market?

During, the projected period North America is anticipated to hold the highest market share. This has been brought to increased public awareness of influenza infections and the treatments that are available, government education initiatives and the development of new vaccines made possible by technological developments.

The existence of significant market players in the area and their substantial R&D spending are further factors contributing to the industry's growth. The influenza pandemic has become more often in North America, boosting the growth of seasonal influenza vaccine market.

The biggest markets for seasonal influenza vaccinations is North America. The high rate of flu in the area and the well-established healthcare system are the main drivers of the market. Children's at the age of six months and older should get the flu shot every year, according to the Centers for Disease Control and Prevention (CDC). The influenza vaccine market in North America is also being driven by a rise in awareness of the value of vaccination.

How will Seasonal Influenza Vaccine Market Fare in Asia Pacific?

The Asia Pacific area is turning into the global influenza vaccine market with the fastest rate of growth. Some of the main reasons propelling market expansion are governments' increased attention on immunization programs, growing per capita healthcare expenditures, and expanding healthcare infrastructure.

Whereas China, India, and Japan are leading the way in public health awareness campaigns because of their sizable populations and public health organizations' activities. Asia has experienced in sales of vaccines as a result of changing lifestyles and an increase in influenza-related diseases in recent years.

It is expected that Asia Pacific would have a higher CAGR over the projection period. The region's market is expected to develop as a result of the growing number of government activities to distribute these vaccines and raise awareness about influenza.

Competitive Landscape

The competitive landscape of the seasonal influenza vaccine market is characterized by several key players and factors that influence market dynamics, innovation, and strategic initiatives. These players completely based on Product portfolio, business segment, business strategies and recent development.

Some of the prominent players operating in the seasonal influenza vaccine market include:

• Sanofi
• Merck & Co
• Novartis
• GlaxoSmithKline
• Changsheng
• Bio-Technology Co., Ltd.
• OSIVAX
• Abbott Laboratories
• Aleph Biomedical.
• AstraZeneca
• SINOVAC
• Vietris Inc.
• BIKEN Co., Ltd
• GSK plc
• Pfizer Inc.
• Vaxess Technologies Inc.
• EMERGEX VACCINES

Latest Developments

• In October 2023, the outcomes of Moderna Inc.'s m-RNA-based vaccination for COVID-19 and influenza were revealed.
• In May 2023, GSK and CureVac launched the phase Ill influenza study for GSK's mRNA-based vaccination.
• In September 2022, Pfizer Inc. declared that the company's quadrivalent modified RNA influenza vaccine candidate has reached the first dose of participants in a pivotal phase 3 clinical study to assess the vaccine's immunogenicity, safety, tolerability, and efficacy.
• In February 2021, Pfizer and BioNTech declared that the COVID-19 vaccine was approved for use in emergency situations in the United States. This approval represented a significant turning point in the global fight against COVID-19 and showed that pharmaceutical companies can quickly create and commercialize vaccines to prevent the spread of infectious illnesses.

Seasonal Influenza Vaccines Market, By Category

• Type:
• Inactivated
• Live Attenuated
• Vaccine Type:
• Quadrivalent
• Trivalent
• Valency:
• Quadrivalent
• Trivalent
• Route of Administration:
• Injection
• Nasal Spray
• Age Group:
• Pediatric
• Adults
• Distribution Channel:
• Hospital & Retail Pharmacies
• Government & Institutional Supply
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL SEASONAL INFLUENZA VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL SEASONAL INFLUENZA VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY TYPE

• 5.1 Overview
• 5.2 Inactivated
• 5.3 Live Attenuated

6 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY VACCINE TYPE

• 6.1 Overview
• 6.2 Quadrivalent
• 6.3 Trivalent

7 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY VALENCY

• 7.1 Overview
• 7.1 Quadrivalent
• 7.1 Trivalent

8 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION

• 8.1 Overview
• 8.1 Injection
• 8.1 Nasal Spray

9 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY AGE GROUP

• 9.1 Overview
• 9.1 Pediatric
• 9.1 Adults

10 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY DISTRIBUTION CHANNEL

• 10.1 Overview
• 10.1 Hospital & Retail Pharmacies
• 10.1 Government & Institutional Supply

11 GLOBAL SEASONAL INFLUENZA VACCINE MARKET, BY GEOGRAPHY

• 11.1 Overview
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 U.K.
  • 11.3.3 France
  • 11.3.4 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Rest of Asia Pacific
• 11.5 Rest of the World
  • 11.5.1 Latin America
  • 11.5.2 Middle East and Africa

12 GLOBAL SEASONAL INFLUENZA VACCINE MARKET COMPETITIVE LANDSCAPE

• 12.1 Overview
• 12.2 Company Market Ranking
• 12.3 Key Development Strategies

13 COMPANY PROFILES

• 13.1 Sanofi
  • 13.1.1 Overview
  • 13.1.2 Financial Performance
  • 13.1.3 Product Outlook
  • 13.1.4 Key Developments
• 13.2 Merck & Co
  • 13.2.1 Overview
  • 13.2.2 Financial Performance
  • 13.2.3 Product Outlook
  • 13.2.4 Key Developments
• 13.3 Novartis
  • 13.3.1 Overview
  • 13.3.2 Financial Performance
  • 13.3.3 Product Outlook
  • 13.3.4 Key Developments
• 13.4 GlaxoSmithKline
  • 13.4.1 Overview
  • 13.4.2 Financial Performance
  • 13.4.3 Product Outlook
  • 13.4.4 Key Developments
• 13.5 Changsheng Bio-Technology Co., Ltd.
  • 13.5.1 Overview
  • 13.5.2 Financial Performance
  • 13.5.3 Product Outlook
  • 13.5.4 Key Developments
• 13.6 Abbott Laboratories
  • 13.6.1 Overview
  • 13.6.2 Financial Performance
  • 13.6.3 Product Outlook
  • 13.6.4 Key Developments
• 13.7 Aleph Biomedical
  • 13.7.1 Overview
  • 13.7.2 Financial Performance
  • 13.7.3 Product Outlook
  • 13.7.4 Key Developments

14 KEY DEVELOPMENTS

• 14.1 Product Launches/Developments
• 14.2 Mergers and Acquisitions
• 14.3 Business Expansions
• 14.4 Partnerships and Collaborations

15 Appendix

• 15.1 Related Research